RENOVA 0.05% Rx
Generic Name and Formulations:
Tretinoin 0.05%; crm.
Bausch Health Companies Inc.
Indications for RENOVA 0.05%:
Adjunct to comprehensive skin care and sunlight avoidance programs in the palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
≥18 years: Wash face with mild soap, pat dry and wait 20–30 minutes before use. Apply a small amount to cover entire affected area lightly once daily in the PM. Do not wash face, or use other skin care products for at least 1 hour after application. Discontinue if sensitivity, irritation, or systemic reactions occur.
<18yrs: not recommended.
Do not use on sunburn, eczema, other chronic skin conditions, or for sun-sensitive patients. Avoid eyes, ears, mouth, angle of nose, mucous membranes, sun, UV light. Increased irritation in extreme weather. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
Avoid photosensitizers, topical irritants, and drying agents.
Local erythema, peeling, dry skin, burning, stinging, pruritus, hypo- or hyperpigmentation.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC